BioCentury
ARTICLE | Preclinical News

Hybrid T cells show anticancer effects

November 14, 2017 10:18 PM UTC

A study published in Cell Metabolism by researchers at Medical University of South Carolina and colleagues showed that the enhanced antitumor effect of a hybrid of T helper types 1 (Th1) and 17 (Th17) cells was dependent on activity of sirtuin 1 (SIRT1) and reduced CD38 expression, suggesting new targets for developing antitumor adoptive T cell therapies.

Th17 cells show promise for cancer immunotherapy due to their "stem cell-like" characteristics that enable them to persist longer in the host. Similarly, Th1 cells display an enhanced antitumor effector function...